Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #21 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 435,863 | 146.5 | 13.7% | 11.0% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 246,660 | 83.9 | 15.3% | 62.7% | 0.32% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 162,454 | 78.2 | 12.2% | 34.6% | 0.79% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 115,910 | 33.3 | 17.3% | 17.2% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 108,736 | 35.4 | 11.2% | -11.0% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,969 | 122.5 | 17.1% | 127.1% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 103,406 | 47.4 | 11.7% | 2.6% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 102,916 | 154.7 | 10.9% | -0.9% | — | 62 | 33 | 71 |
| Wockhardt Limited (this stock) | 34,388 | 96.6 | 3.8% | 41.8% | — | 60 | 33 | 50 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 929 | 116 | 107 | ₹ |
| March 31, 2026 | 965 | 189 | 164 | ₹ |
| Dec. 31, 2025 | 888 | 67 | 61 | ₹ |
| Sept. 30, 2025 | 782 | 91 | 82 | ₹ |
| June 30, 2025 | 738 | -109 | -108 | ₹ |
| March 31, 2025 | 743 | -22 | -45 | ₹ |
| Dec. 31, 2024 | 721 | 21 | 20 | ₹ |
| Sept. 30, 2024 | 809 | -9 | -16 | ₹ |
| June 30, 2024 | 739 | -6 | -16 | ₹ |
| March 31, 2024 | 700 | -180 | -177 | ₹ |
| Dec. 31, 2023 | 701 | -87 | -86 | ₹ |
| Sept. 30, 2023 | 753 | -35 | -73 | ₹ |
| June 30, 2023 | 644 | -118 | -136 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 3,373 | 238 | 199 |
| March 31, 2025 | 3,012 | -16 | -57 |
| March 31, 2024 | 2,798 | -420 | -472 |
| March 31, 2023 | 2,651 | -624 | -621 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 390 | -241 | -54 | 136 | 254 |
| March 31, 2025 | -22 | -783 | 409 | 94 | -116 |
| March 31, 2024 | 219 | -137 | 334 | 59 | 160 |
| March 31, 2023 | 153 | -125 | -315 | 42 | 111 |
| March 31, 2022 | 413 | -201 | -71 | 118 | 295 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 8,615 | 5,281 | 4,859 | 607 | 1,518 | 2,606 | 1,622 | 217 | 1,618 | 887 |
| March 31, 2025 | 8,135 | 4,657 | 4,272 | 648 | 1,211 | 2,465 | 2,042 | 112 | 1,718 | 725 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
